Electronic Supplementary Information

Xyloplains A-F, six new guaiane-type sesquiterpenoid dimers from

Xylopia vielana

Yang-Guo Xie^{a, 1}, Weiyue Zhang^{a, 1}, Sheng-lan Zhu^a, Tao-fang Cheng^a, Guo-jing Wu^a, Ishaq Muhammad^a Shi-kai Yan^a, Yan Zhang^{a*}, Hui-zi Jin^{a*}, Wei-dong Zhang^{a, b*}

^aSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, P. R. China.

^bSchool of Pharmacy, Second Military Medical University, Shanghai 200433, P. R.

China.

*Corresponding authors: E-mail: wdzhangy@hotmail.com (W. D. Zhang); kimhz@sjtu.edu.cn; zhangyan_sjtu@sjtu.edu.cn

Fax: +86-21-34205989; Tel: +86-21-34205989 (H. Z. Jin)

¹These authors contributed equally to this work.

Content

Fig. S1¹H NMR spectrum (500 MHz, Chloroform-d) of compound 1 Fig. S2¹³C NMR spectrum (125 MHz, Chloroform-*d*) of compound 1 Fig. S3 DEPT spectrum (125 MHz, Chloroform-d) of compound 1 Fig. S4 ¹H-¹H COSY spectrum (500 MHz, Chloroform-*d*) of compound 1 Fig. S5 HSQC spectrum (500 MHz, Chloroform-d) of compound 1 Fig. S6 HMBC spectrum (500 MHz, Chloroform-d) of compound 1 Fig. S7 NOESY spectrum (500 MHz, Chloroform-d) of compound 1 Fig. S8 HR-ESI-MS spectrum of compound 1 Fig. S9 ¹H NMR spectrum (500 MHz, CD₃OD) of compound 2 Fig. S10¹³C NMR spectrum (125 MHz, CD₃OD) of compound 2 Fig. S11 DEPT spectrum (125 MHz, CD₃OD) of compound 2 Fig. S12 ¹H-¹H COSY spectrum (500 MHz, CD₃OD) of compound 2 Fig. S13 HSQC spectrum (500 MHz, CD₃OD) of compound 2 Fig. S14 HMBC spectrum (500 MHz, CD₃OD) of compound 2 Fig. S15 NOESY spectrum (500 MHz, CD₃OD) of compound 2 Fig. S16 HR-ESI-MS spectrum of compound 2 Fig. S17 ¹H NMR spectrum (500 MHz, CD₃OD) of compound **3** Fig. S18¹³C NMR spectrum (125 MHz, CD₃OD) of compound 3 Fig. S19 DEPT spectrum (125 MHz, CD₃OD) of compound 3 Fig. S20 ¹H-¹H COSY spectrum (500 MHz, CD₃OD) of compound 3 Fig. S21 HSQC spectrum (500 MHz, CD₃OD) of compound 3 Fig. S22 HMBC spectrum (500 MHz, CD₃OD) of compound 3 Fig. S23 NOESY spectrum (500 MHz, CD₃OD) of compound 3 Fig. S24 HR-ESI-MS spectrum of compound 3 Fig. S25 ¹H NMR spectrum (500 MHz, Chloroform-*d*) of compound 4 Fig. S26¹³C NMR spectrum (125 MHz, Chloroform-d) of compound 4 Fig. S27 DEPT spectrum (125 MHz, Chloroform-d) of compound 4 Fig. S28 ¹H-¹H COSY spectrum (500 MHz, Chloroform-*d*) of compound 4 Fig. S29 HSQC spectrum (500 MHz, Chloroform-d) of compound 4 Fig. S30 HMBC spectrum (500 MHz, Chloroform-d) of compound 4 Fig. S31 NOESY spectrum (500 MHz, Chloroform-d) of compound 4 Fig. S32 HR-ESI-MS spectrum of compound 4 Fig. S33 ¹H NMR spectrum (500 MHz, Chloroform-d:CD₃OD 1:2) of compound 5 Fig. S34 ¹³C NMR spectrum (125 MHz, Chloroform-d:CD₃OD 1:2) of compound 5 Fig. S35 DEPT spectrum (125 MHz, Chloroform-d:CD₃OD 1:2) of compound 5 Fig. S36 ¹H-¹H COSY spectrum (500 MHz, Chloroform-d:CD₃OD 1:2) of compound 5 Fig. S37 HSQC spectrum (500 MHz, Chloroform-d:CD₃OD 1:2) of compound 5

Fig. S38 HMBC spectrum (500 MHz, Chloroform-*d*:CD₃OD 1:2) of compound 5
Fig. S39 NOESY spectrum (500 MHz, Chloroform-*d*:CD₃OD 1:2) of compound 5
Fig. S40 HR-ESI-MS spectrum of compound 5
Fig. S41 ¹H NMR spectrum (500 MHz, Chloroform-*d*) of compound 6
Fig. S42 ¹³C NMR spectrum (125 MHz, Chloroform-*d*) of compound 6
Fig. S43 DEPT spectrum (125 MHz, Chloroform-*d*) of compound 6
Fig. S44 ¹H-¹H COSY spectrum (500 MHz, Chloroform-*d*) of compound 6
Fig. S45 HSQC spectrum (500 MHz, Chloroform-*d*) of compound 6
Fig. S46 HMBC spectrum (500 MHz, Chloroform-*d*) of compound 6
Fig. S46 HMBC spectrum (500 MHz, Chloroform-*d*) of compound 6
Fig. S47 NOESY spectrum (500 MHz, Chloroform-*d*) of compound 6
Fig. S48 HR-ESI-MS spectrum of compound 6
Fig. S48 HR-ESI-MS spectrum of compound 6

Fig. S50 Inhibitory effect of compounds 1–6 (50 μ M 10 μ M) against NO production in LPS-stimulated RAW264.7macrophages and cytotoxic effects of compounds 1–6 in the MTT assay (Raw 264.7 cells). [C: control; L: LPS group; P: positive group] Parthenolide (10 μ M) was used as a positive control.



Fig. S1 ¹H NMR spectrum (500 MHz, Chloroform-d) of compound 1



Fig. S2 ¹³C NMR spectrum (125 MHz, Chloroform-*d*) of compound 1



Fig. S3 DEPT spectrum (125 MHz, Chloroform-d) of compound 1



Fig. S4 ¹H-¹H COSY spectrum (500 MHz, Chloroform-d) of compound 1



Fig. S5 HSQC spectrum (500 MHz, Chloroform-d) of compound 1



Fig. S6 HMBC spectrum (500 MHz, Chloroform-d) of compound 1



Fig. S7 NOESY spectrum (500 MHz, Chloroform-d) of compound 1



Fig. S8 HR-ESI-MS spectrum of compound 1



Fig. S9 ¹H NMR spectrum (500 MHz, CD₃OD) of compound 2



Fig. S10 ¹³C NMR spectrum (125 MHz, CD₃OD) of compound 2



Fig. S11 DEPT spectrum (125 MHz, CD_3OD) of compound 2



Fig. S12 ¹H-¹H COSY spectrum (500 MHz, CD₃OD) of compound 2



Fig. S13 HSQC spectrum (500 MHz, CD₃OD) of compound 2



Fig. S14 HMBC spectrum (500 MHz, CD₃OD) of compound 2



Fig. S15 NOESY spectrum of compound 2



Fig. S16 HR-ESI-MS spectrum of compound 2



Fig. S17 ¹H NMR spectrum (500 MHz, CD₃OD) of compound 3



Fig. S18 ¹³C NMR spectrum (125 MHz, CD₃OD) of compound 3



Fig. S19 DEPT spectrum (125 MHz, CD_3OD) of compound 3





Fig. S21 HSQC spectrum (500 MHz, CD₃OD) of compound 3



Fig. S22 HMBC spectrum (500 MHz, CD₃OD) of compound 3



Fig. S23 NOESY spectrum (500 MHz, CD₃OD) of compound 3



Fig. S24 HR-ESI-MS spectrum of compound 3



Fig. S25 ¹H NMR spectrum (500 MHz, Chloroform-d) of compound 4



Fig. S26¹³C NMR spectrum (125 MHz, Chloroform-*d*) of compound 4



Fig. S27 DEPT spectrum (125 MHz, Chloroform-d) of compound 4



Fig. S28 ¹H-¹H COSY spectrum (500 MHz, Chloroform-*d*) of compound 4



Fig. S29 HSQC spectrum (500 MHz, Chloroform-d) of compound 4



Fig. S30 HMBC spectrum (500 MHz, Chloroform-d) of compound 4



Fig. S31 NOESY spectrum (500 MHz, Chloroform-d) of compound 4



Fig. S32 HR-ESI-MS spectrum of compound 4



Fig. S33 ¹H NMR spectrum (500 MHz, Chloroform-d:CD₃OD 1:2) of compound 5



Fig. S34 ¹³C NMR spectrum (125 MHz, Chloroform-d:CD₃OD 1:2) of compound 5



Fig. S35 DEPT spectrum (125 MHz, Chloroform-d:CD₃OD 1:2) of compound 5



Fig. S36 ¹H-¹H COSY spectrum (500 MHz, Chloroform-*d*:CD₃OD 1:2) of compound 5



Fig. S37 HSQC spectrum (500 MHz, Chloroform-d:CD₃OD 1:2) of compound 5



Fig. S38 HMBC spectrum (500 MHz, Chloroform-d:CD₃OD 1:2) of compound 5







Fig. S40 HR-ESI-MS spectrum of compound 5



Fig. S42 ¹³C NMR spectrum (125 MHz, Chloroform-*d*) of compound 6



Fig. S43 DEPT spectrum (125 MHz, Chloroform-d) of compound 6



Fig. S44 ¹H-¹H COSY spectrum (500 MHz, Chloroform-*d*) of compound 6



Fig. S45 HSQC spectrum (500 MHz, Chloroform-d) of compound 6





Fig. S47 NOESY spectrum (500 MHz, Chloroform-d) of compound 6



Fig. S48 HR-ESI-MS spectrum of compound 6



Fig. S49 The CD spectrum of compounds ${\bf 5}\;$ and ${\bf 6}\;$



Fig. S50 Inhibitory effect of compounds 1-6 (50 μ M 10 μ M) against NO production in LPS-stimulated RAW264.7macrophages and cytotoxic effects of compounds 1-6 in the MTT assay (Raw 264.7 cells). [C: control; L: LPS group; P: positive group] Parthenolide (10 μ M) was used as a positive control.